CD27 is a costimulatory receptor belonging to the TNF family, which is expressed on naive T and B cells as well as NK cells. CD27 is a membrane glycoprotein similar to CD40, OX40, and 4-1BB. This receptor is required for the generation and long-term maintenance of T-cell immunity. It binds to the ligand CD70 and plays a key role in regulating B cell activation and immunoglobulin synthesis. When CD27 binds to CD70, the signaling cascade leads to differentiation and clonal expansion of T cells. The cascade also increases the survival and memory of cytotoxic T cells and increases the production of certain cytokines. Immunologists are interested in CD27 as a costimulatory immune checkpoint molecule and a target for anticancer drugs in clinical trials.

Our Services

• Target Analysis

The failure of targeted drug development is often attributed to insufficient understanding of the functional role of target protein molecules under physiological conditions inside and outside cells. Therefore, CD27 target validation should be carried out first before the discovery of hit compounds through screening in the early stages of drug development. CD ComputaBio can complete CD27 target validation through the following technology platforms:

• Over 100 cell lines across different disease backgrounds available for target validation
• CRISPR/Cas9 technology to knock out target protein genes
• Target validation with reversible or irreversible inhibitors

• Mechanism of Action Studies

We use the information of target and candidate to prioritize work from hit-to-lead or drive the hit discovery process when a single mode of action is required. We applied biochemical techniques as well as biophysical orthogonal readouts.

• Biophysics

Our team has successfully used several biophysical techniques such as SPR, LC-MS and NMR. Our computational chemistry department greatly facilitates the interpretation of structural biology data and facilitates the modeling of observed molecular interactions.

• Binding kinetics

We adopt the method of modeling targets and small molecules, and use the technical means of molecular dynamics simulation and allosteric site mutation to simulate the interaction between candidate compounds and CD27 in various solvents, and dynamically display the mechanism of action.

• In Silico and PBPK modelling

CD ComputaBio's experienced modeling and simulation team works with your entire project team to provide guidance throughout the life of the project, helping to:

• Define early discovery screening cascades, interpret in vitro data and recommend options for progression to in vivo studies.
• Dosing and dosing regimen recommendations for pharmacodynamic (PD) studies through PK and PK/PD modeling and simulations.
• Predict effective pharmacological doses (combining PK predictions with PK/PD assumptions).
• Assessing the risk of drug-drug Interactions

Our Capabilities

Our team can support your hit identification efforts through strategy design, analysis development and screening activities. Our skilled assay development team can design the right assay for your unique needs. Once a strategy is in place and tools are ready, our screening team is ready to support you in your hit identification efforts. It includes providing access to our large, curated and diverse library of compounds, virtual screening and curated fragment libraries.

• High-throughput screening facility with multiple detection technologies
• Curated library of 720,000 compounds
• Robust and effective screening strategy